Predictive Technology Group and Atrin Pharmaceuticals LLC are entering into a collaboration agreement to develop molecular diagnostic tools to facilitate improved selection of cancer patients who would most benefit from treatment with DNA Damage and Response (DDR) inhibitors, including Atrin's and other small molecule ATR inhibitors. Atrin and Predictive will jointly utilize Predictive Laboratories' sequencing capabilities and genomics expertise to identify cancer patients with specific molecular markers that predict the level of clinical response to Atrin's, and other, targeted therapies. This is intended to improve patient outcomes as well as improve Atrin's ability to successfully progress its product pipeline, and upon commercialization, improve on the treatments for women with cancer.

The collaboration will help optimize the safety and clinical efficacy of Atrin's targeted cancer therapeutics and other DDR drug candidates. Atrin will have access to Predictive's proprietary GenDB databases and women's health biobank to better understand the clinical spectrum of germline mutations in DDR pathways. The companies will also study common gynecologic disorders, such as endometriosis, associated with the development of cancers in affected patients.

The goal of this collaboration is to develop actionable predictive molecular and companion diagnostics and therapeutics for these common disorders and related cancers. CLSA Capital Markets Limited, a CITIC Securities Company, under its mandate with Predictive Technology Group, will continue to introduce potential strategic partners and provide relevant regulatory guidance to Predictive Technology Group.